The hopeful buzz around the drug Remdesivir and its potential as a COVID-19 treatment grew so deafening Wednesday, it triggered an unexpected surge in the financial markets. “This is not a silver bullet, this is not going to kill the werewolf,” said Dr. Gerald Evans, chair of the infectious diseases division at Queen’s University. The excitement this week revolved around results from a Remdesivir trial where patients were randomly selected to receive either the drug or a placebo, the gold standard in medical research. The medication has been offered to Canadian patients as part of at least two studies. “Everybody right now around the world wants to see a silver lining in what otherwise looks like a pretty dark cloud,” he said.

Source: National Post April 30, 2020 22:11 UTC